8A20 - Alzheimer's Disease: Complete ICD-11 Coding Guide

1. Introduction

Alzheimer's Disease represents the most common form of neurodegenerative dementia, characterized by progressive and irreversible cognitive decline that primarily affects memory, thinking, behavior, and the ability to perform daily activities. This devastating neurological condition gradually compromises patients' autonomy, profoundly impacting not only their lives but also those of family members and caregivers.

The clinical importance of Alzheimer's Disease transcends the individual aspect, constituting one of the greatest global public health challenges today. With worldwide population aging, the prevalence of this condition has increased significantly, becoming one of the leading causes of dependence and institutionalization in elderly individuals. The disease typically manifests after age 65, although early-onset forms can occur before this age.

The economic and social impact of Alzheimer's Disease is immense, involving direct costs with medical treatment, medications, home and institutional care, in addition to indirect costs related to loss of caregiver productivity. The emotional and physical burden on family members who assume the caregiver role also represents a critical aspect of this condition.

Correct coding of Alzheimer's Disease in the ICD-11 system is fundamental for multiple purposes: it enables precise epidemiological tracking, facilitates appropriate allocation of health resources, aids in public policy planning, ensures appropriate reimbursement of procedures and treatments, and enables robust clinical research. Adequate documentation is also essential for establishing eligibility for social benefits and specialized support that patients frequently require.

2. Correct ICD-11 Code

Code: 8A20

Description: Alzheimer's disease

Parent category: Disorders with neurocognitive impairment as a principal feature

The code 8A20 in the International Classification of Diseases, 11th Revision (ICD-11), specifically designates Alzheimer's disease, distinguishing it from other forms of dementia and neurocognitive disorders. This code encompasses all presentations of the disease, including both early-onset forms (before age 65) and late-onset forms (after age 65).

The classification within the category of disorders with neurocognitive impairment as a principal feature reflects the essentially cognitive nature of this condition. Alzheimer's disease is characterized by a specific pattern of cerebral deterioration, with accumulation of beta-amyloid protein plaques and neurofibrillary tangles of tau protein, resulting in progressive neuronal death and cerebral atrophy.

This code should be used when the diagnosis of Alzheimer's disease has been established through recognized clinical criteria, supported by neuropsychological evaluation, neuroimaging studies, and exclusion of other causes of dementia. The specificity of this code allows clear differentiation from other neurodegenerative dementias, facilitating appropriate clinical management and longitudinal follow-up of patients.

3. When to Use This Code

The code 8A20 should be applied in specific clinical situations where Alzheimer's Disease has been adequately diagnosed. Below, we present detailed practical scenarios:

Scenario 1: Progressive Cognitive Decline with Amnestic Impairment

A 72-year-old patient presents with a two-year history of progressive forgetfulness, initially of recent events, progressing to difficulty recalling names of close family members and important appointments. Neuropsychological evaluation demonstrates significant deficit in episodic memory, with relative initial preservation of other cognitive functions. Cerebral magnetic resonance imaging reveals bilateral hippocampal and medial temporal atrophy, consistent with Alzheimer's Disease. In this case, code 8A20 is appropriate.

Scenario 2: Dementia with Insidious Onset and Gradual Progression

A 68-year-old patient with family complaints of subtle behavioral changes over three years, including loss of initiative, difficulty planning complex activities, and progressive spatial disorientation. Cognitive examination reveals impairment in multiple domains, including memory, executive function, and visuospatial abilities. Cerebrospinal fluid biomarkers show characteristic Alzheimer's pattern (reduced beta-amyloid and elevated tau). Code 8A20 is appropriate for this clinical presentation.

Scenario 3: Early-Onset Alzheimer's Disease

A 58-year-old patient with notable cognitive decline over the past 18 months, affecting work performance and daily activities. Positive family history of early-onset dementia. Neuropsychological evaluation demonstrates deficits in memory, language, and executive function. Functional neuroimaging (PET scan) shows bilateral temporoparietal hypometabolism. After exclusion of other causes, the diagnosis of early-onset Alzheimer's Disease is established, justifying the use of code 8A20.

Scenario 4: Progression from Mild Cognitive Impairment to Dementia

A 75-year-old patient previously diagnosed with amnestic mild cognitive impairment, followed for three years, now presents with significant functional decline, with inability to manage finances, need for supervision with medications, and frequent temporal disorientation. Reassessment confirms progression to dementia due to Alzheimer's Disease, making code 8A20 appropriate at this time.

Scenario 5: Diagnosis Confirmed by Multidisciplinary Evaluation

A 70-year-old patient referred to a specialized clinic for cognitive disorders with memory complaints. After comprehensive evaluation including detailed clinical history, neurological examination, complete neuropsychological battery, cerebral magnetic resonance imaging, and functional assessment, the multidisciplinary team establishes consensual diagnosis of Alzheimer's Disease. Code 8A20 adequately reflects this diagnostic conclusion.

Scenario 6: Atypical Presentation with Diagnostic Confirmation

A 65-year-old patient with predominant complaints of language difficulty and progressive anomia over two years. Although the presentation is atypical, investigation with biomarkers and neuroimaging confirms underlying Alzheimer's pathology. Even in variant presentations, when Alzheimer's pathology is confirmed, code 8A20 remains appropriate.

4. When NOT to Use This Code

It is crucial to recognize situations where code 8A20 should not be applied, avoiding coding errors that may compromise clinical management and epidemiological records.

Mild Cognitive Impairment (MCI): When the patient presents with measurable cognitive decline but maintains functional independence in daily activities, the diagnosis does not yet characterize dementia. Code 8A20 is reserved for cases where there is significant functional impairment. MCI requires different coding, even when there is risk of progression to Alzheimer disease.

Vascular Dementia: Patients with cognitive decline related to cerebrovascular events, multiple infarcts, or cerebral small vessel disease should receive the specific code for vascular dementia. Even if there is some concomitant Alzheimer pathology, if the vascular etiology is predominant, code 8A20 is not the most appropriate.

Lewy Body Disease: This condition presents distinctive features including cognitive fluctuations, early visual hallucinations, parkinsonism, and neuroleptic sensitivity. Despite sharing some symptoms with Alzheimer disease, it requires the specific code 8A22.

Frontotemporal Degeneration: Patients with prominent early behavioral changes, disinhibition, marked apathy, or primary progressive aphasia, especially with onset before age 65, frequently have frontotemporal degeneration, coded as 8A23, not 8A20.

Reversible Secondary Dementias: Conditions such as hypothyroidism, vitamin B12 deficiency, normal pressure hydrocephalus, or medication-related dementia should not be coded as Alzheimer Disease. These conditions require specific codes for their primary etiologies.

Delirium or Acute Confusion: Acute confusional states, even in elderly patients, should not be coded as 8A20. Delirium has sudden onset and fluctuating course, differing fundamentally from the insidious and progressive decline of Alzheimer Disease.

5. Coding Step by Step

Step 1: Assess Diagnostic Criteria

Diagnostic confirmation of Alzheimer's Disease requires systematic and comprehensive evaluation. First, progressive cognitive decline must be documented through detailed clinical history, obtained from both the patient and reliable informants. The decline must be evident in at least two cognitive domains, with episodic memory typically being the earliest affected domain.

Formal neuropsychological evaluation is essential, utilizing validated instruments such as Mini-Cog, Montreal Cognitive Assessment (MoCA), episodic memory tests, executive function assessment, and language tests. These instruments provide objective documentation of cognitive impairment and its severity.

Functional impairment must be clearly established, demonstrating that cognitive deficits significantly interfere with instrumental or basic activities of daily living. Functional scales such as the Instrumental Activities of Daily Living (IADL) Scale and Basic Activities of Daily Living (BADL) Scale assist in this evaluation.

Neuroimaging studies, preferably brain magnetic resonance imaging, should be performed to assess cerebral atrophy, particularly in medial temporal and hippocampal regions, and to exclude other structural causes of dementia. When available, cerebrospinal fluid biomarkers or PET-scan with amyloid tracers may provide additional confirmation.

Step 2: Verify Specifiers

After confirming the diagnosis, important characteristics of the clinical presentation should be specified. Age of onset is relevant, distinguishing early-onset forms (before age 65) from late-onset forms (after age 65), although both are coded as 8A20.

Dementia severity must be documented, classifying it as mild, moderate, or severe based on the degree of functional and cognitive impairment. In the mild stage, the patient presents subtle difficulties but maintains relative independence. In the moderate stage, assistance is needed for complex activities. In the severe stage, there is complete dependence for personal care.

Additional clinical features such as presence of neuropsychiatric symptoms (agitation, depression, psychosis, sleep disturbances), motor symptoms, or associated medical complications should be documented, as they influence clinical management, although they do not change the primary code.

Duration of symptoms and rate of progression should also be recorded, as they provide prognostic information and assist in planning longitudinal care.

Step 3: Differentiate from Other Codes

Differentiation from code 8A21 (Primary Progressive Aphasias): Primary progressive aphasias, including progressive primary aphasia, posterior cortical atrophy, and behavioral variant, present predominant focal impairment in specific domains (language, visuospatial abilities, behavior) with relative initial preservation of episodic memory. When memory is the primary affected domain from onset, with a more generalized atrophy pattern, code 8A20 is more appropriate.

Differentiation from code 8A22 (Lewy Body Disease): Lewy Body Disease is distinguished by pronounced cognitive fluctuations, early complex visual hallucinations, spontaneous parkinsonian symptoms, and REM sleep behavior disorder. The presence of these characteristic features indicates 8A22 rather than 8A20, even when there is pathological overlap.

Differentiation from code 8A23 (Frontotemporal Lobar Degeneration): Frontotemporal degeneration is characterized by prominent early behavioral changes (disinhibition, apathy, loss of empathy, stereotyped behaviors) or primary progressive aphasia, often with onset before age 65. Neuroimaging shows predominant frontotemporal atrophy. When these characteristics are present, 8A23 is more appropriate than 8A20.

Step 4: Required Documentation

Adequate documentation to justify code 8A20 should include:

Checklist of Mandatory Information:

• Detailed history of cognitive decline, including onset, progression, and affected domains
• Report from reliable informant corroborating cognitive and functional changes
• Results of formal cognitive assessment with specific scores
• Functional evaluation documenting impairment in daily activities
• Results of neuroimaging studies with description of relevant findings
• Exclusion of alternative causes of dementia (laboratory tests, medication history)
• Neurological evaluation ruling out other neurological conditions
• Documentation of neuropsychiatric symptoms when present
• Staging of dementia severity

The medical record should present clear clinical reasoning explaining how diagnostic criteria were met and how other causes of dementia were excluded. This robust documentation not only justifies coding but also facilitates continuity of care and communication among professionals.

6. Complete Practical Example

Clinical Case

Mrs. M.S., 74 years old, retired teacher, is brought to a neurology consultation by her daughter due to concerns about memory. The daughter reports that over the past two and a half years, the mother has presented progressive forgetfulness, initially attributed to normal aging. Recently, the forgetfulness has become more evident: M.S. repeats the same questions several times, forgets important appointments, and last week became lost when returning from a familiar location.

The daughter also notes that M.S. has abandoned activities she enjoyed, such as reading and crossword puzzles, claiming "I cannot concentrate." There was a concerning incident where M.S. left the stove on after preparing lunch. The patient has been presenting progressive difficulty managing her finances, having paid the same bill twice and forgotten others.

On history, M.S. acknowledges "some forgetfulness" but minimizes its extent. She denies depressive symptoms, hallucinations, or motor changes. There is no history of cerebrovascular events. Family history reveals that the patient's mother developed dementia at age 80. M.S. has controlled hypertension and does not use medications that may affect cognition.

On neurological examination, M.S. is alert, oriented to person and place, but disoriented to time (does not know the day of the month or the correct year). The Mini-Cog State Examination results in 21/30 points, with significant losses in recall memory, temporal orientation, and calculation. On the clock drawing test, she presents difficulty positioning the numbers correctly.

Formal neuropsychological evaluation reveals marked deficit in episodic memory (unable to recall information after a 20-minute interval, even with cues), mild to moderate executive dysfunction (difficulty with planning and mental flexibility), and mild impairment in visuospatial abilities. Language and naming are relatively preserved.

Laboratory tests (complete blood count, thyroid function, vitamin B12, folic acid, renal and hepatic function) are within normal limits. Brain magnetic resonance imaging demonstrates moderate bilateral hippocampal atrophy, medial temporal cortical atrophy, and ventricular enlargement, without significant vascular lesions or other structural abnormalities.

Step-by-Step Coding

Criteria Analysis:

1. Confirmed progressive cognitive decline: History of two and a half years of gradual deterioration, corroborated by a reliable informant and objectively documented by cognitive tests.

2. Impairment in multiple domains: Episodic memory (primary domain), executive function, temporal orientation, and visuospatial abilities affected.

3. Significant functional impairment: Inability to manage finances, safety risk (stove left on, spatial disorientation), abandonment of complex activities.

4. Neuroimaging pattern consistent: Bilateral hippocampal and medial temporal atrophy, characteristic pattern of Alzheimer's Disease.

5. Exclusion of other causes: Normal laboratory tests, absence of vascular history, no causative medications, no symptoms suggestive of other dementias.

6. Insidious onset and gradual progression: Typical characteristic of Alzheimer's, differentiating from vascular causes or other conditions.

Code Chosen: 8A20 - Alzheimer's Disease

Complete Justification:

Code 8A20 is appropriate for this case based on the classic clinical presentation of Alzheimer's Disease. The patient presents progressive cognitive decline with insidious onset, predominantly amnestic, with significant functional impairment interfering with instrumental activities of daily living. The neuropsychological evaluation objectively documents prominent deficit in episodic memory, the cognitive domain most characteristically affected in Alzheimer's.

Neuroimaging reveals bilateral hippocampal atrophy, a finding highly suggestive of Alzheimer's pathology. The absence of significant vascular lesions, the exclusion of metabolic or medication-related causes, and the lack of features suggestive of other neurodegenerative dementias (without fluctuations, hallucinations, parkinsonism, or prominent early behavioral changes) strengthen the diagnosis.

The age of onset (72 years) and progression over two and a half years are consistent with late-onset Alzheimer's Disease. The positive family history for dementia also supports the diagnosis.

Applicable Complementary Codes:

Depending on the coding system and documentation needs, additional codes may be considered to capture comorbidities and complications:

• Code for arterial hypertension (coexisting medical condition)
• Codes for specific neuropsychiatric symptoms if they develop (agitation, depression, sleep disturbances)
• Code for severity staging (mild to moderate dementia in this case)

7. Related Codes and Differentiation

Within the Same Category

8A21: Progressive Focal Atrophies

When to use 8A21 vs. 8A20: The code 8A21 is appropriate when the clinical presentation is dominated by focal impairment in a specific cognitive domain, with relative initial preservation of other domains, particularly episodic memory. Examples include primary progressive aphasia (progressive language deterioration), posterior cortical atrophy (predominant visuospatial impairment), or behavioral variant with focal atrophy.

Main difference: While 8A20 is characterized by predominant amnestic impairment from onset with a more generalized atrophy pattern, 8A21 presents with focal syndrome with an atrophy pattern corresponding to the specific affected brain region. If memory is the primary domain impaired from onset, 8A20 is more appropriate; if language, visuospatial abilities, or behavior are predominantly affected with relative memory preservation, consider 8A21.

8A22: Lewy Body Disease

When to use 8A22 vs. 8A20: The code 8A22 should be used when core features of Lewy Body Disease are present: pronounced cognitive fluctuations (significant variations in attention and alertness), complex and recurrent visual hallucinations, spontaneous parkinsonism (rigidity, bradykinesia, tremor), and/or REM sleep behavior disorder.

Main difference: Alzheimer's disease (8A20) presents with more stable progressive cognitive decline, without the marked fluctuations characteristic of Lewy bodies. Visual hallucinations, when present in Alzheimer's disease, generally occur in more advanced stages, whereas in 8A22 they are early and prominent. Spontaneous parkinsonian symptoms strongly favor 8A22. Neuroleptic hypersensitivity is characteristic of 8A22, not 8A20.

8A23: Frontotemporal Lobar Degeneration

When to use 8A23 vs. 8A20: The code 8A23 is appropriate when there are prominent early behavioral changes (social disinhibition, marked apathy, loss of empathy, compulsive or stereotyped behaviors) or primary progressive aphasia, often with onset before age 65. Neuroimaging demonstrates predominant frontotemporal atrophy.

Main difference: Alzheimer's disease (8A20) is characterized by predominant amnestic impairment with relative initial preservation of personality and social behavior. Behavioral changes, when present, generally occur in more advanced stages. In contrast, 8A23 presents with behavioral or language changes as prominent initial manifestations, with relatively preserved episodic memory in early stages. The distribution of brain atrophy differs significantly: medial temporal and hippocampal in 8A20 versus frontotemporal in 8A23.

Differential Diagnoses

Vascular Dementia: Distinguished by history of cerebrovascular events, more abrupt onset or stepwise progression, presence of prominent vascular risk factors, and neuroimaging showing strategic infarcts or extensive small vessel disease. The pattern of cognitive deficits may be more heterogeneous.

Mild Cognitive Impairment: Differentiated by preservation of functional independence in daily activities, despite measurable cognitive deficits. When significant functional impairment is present, the diagnosis progresses to dementia.

Depression Pseudodementia: Can mimic dementia in elderly patients, but is characterized by more acute onset, cognitive complaints disproportionate to objective performance, prominent depressive symptoms, and potential reversibility with antidepressant treatment.

Normal Pressure Hydrocephalus: Classic triad of gait disturbance (gait apraxia), urinary incontinence, and dementia. Neuroimaging shows ventriculomegaly disproportionate to cortical atrophy.

8. Differences with ICD-10

In ICD-10, Alzheimer's Disease was coded primarily as G30 (Alzheimer's Disease) with subdivisions: G30.0 (Early-onset Alzheimer's Disease), G30.1 (Late-onset Alzheimer's Disease), G30.8 (Other forms of Alzheimer's Disease), and G30.9 (Alzheimer's Disease, unspecified). Alternatively, codes from the F00 series (Dementia in Alzheimer's Disease) were used when the focus was on the demential aspect.

In ICD-11, coding was simplified and consolidated under the code 8A20, eliminating the need for multiple codes and complex subdivisions. This change reflects a more integrated approach, recognizing that Alzheimer's Disease is essentially a neurocognitive condition, without the need for dual coding between neurological and psychiatric chapters.

Main changes in ICD-11:

The ICD-11 structure integrates neurological and cognitive aspects into a single coherent category of "Disorders with neurocognitive impairment as a main feature," eliminating the previous fragmentation between chapters. Code 8A20 encompasses all forms of Alzheimer's Disease, regardless of age of onset, simplifying coding.

ICD-11 offers greater flexibility for additional specifiers through extension codes, allowing more detailed documentation of severity, clinical features, and complications without the need for multiple primary codes. This approach facilitates clinical coding while maintaining the ability to capture important nuances.

Practical impact of these changes:

Simplification reduces coding errors and ambiguity, particularly in borderline cases between age categories. Integration eliminates confusion about which code to use (neurological versus psychiatric), promoting consistency in records. For healthcare professionals, the transition requires familiarization with the new structure, but results in a more intuitive and efficient coding process. For health information systems, it enables more accurate epidemiological tracking and more robust international comparisons.

9. Frequently Asked Questions

1. How is Alzheimer's Disease diagnosed?

The diagnosis of Alzheimer's Disease is essentially clinical, based on a comprehensive evaluation that includes a detailed history of cognitive decline obtained from the patient and informants, neurological examination, formal neuropsychological evaluation to objectively document cognitive deficits, and functional assessment demonstrating impairment in daily activities. Neuroimaging studies, particularly brain magnetic resonance imaging, are fundamental for evaluating atrophy patterns and excluding other causes. When available, biomarkers in cerebrospinal fluid or PET-scan with amyloid tracers can provide additional confirmation, although they are not mandatory for clinical diagnosis. Laboratory tests are performed to exclude reversible causes of dementia. Definitive diagnosis can only be confirmed by post-mortem neuropathological examination, but clinical diagnosis has good accuracy when performed by specialists.

2. Is treatment available in public health systems?

Treatment for Alzheimer's Disease is generally available in public health systems in most countries, although the extent of coverage varies. Approved medications include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine, which can provide modest symptomatic benefit. In addition to pharmacological treatment, non-pharmacological approaches including cognitive stimulation, psychosocial support, caregiver guidance, and management of neuropsychiatric symptoms are essential components of care. Recently, disease-modifying therapies targeting amyloid pathology have been approved in some jurisdictions, although their availability in public systems remains limited due to high costs and specialized infrastructure requirements. Access to multidisciplinary specialized dementia services varies considerably among different regions and health systems.

3. How long does treatment last?

Treatment of Alzheimer's Disease is continuous and lifelong, since it is a progressive condition with no currently available cure. Symptomatic medications are typically maintained as long as perceived benefit and good tolerability persist, and may be used for several years. Regular medical follow-up is necessary to monitor disease progression, adjust medications, manage emerging neuropsychiatric symptoms, and provide continuous support to the patient and family. As the disease progresses to advanced stages, the focus of treatment frequently shifts from pharmacological interventions to palliative and comfort care. Support for caregivers should be continuous throughout the entire disease trajectory, recognizing the substantial impact on family members.

4. Can this code be used in medical certificates?

Yes, code 8A20 can and should be used in medical certificates when appropriate, particularly to document the need for work leave, justify requests for social or disability benefits, or establish eligibility for specialized support services. However, important ethical considerations must be observed, including respect for confidentiality and prior discussion with the patient (when possible) and family about disclosure of the diagnosis. In some contexts, it may be appropriate to use more general terms such as "neurocognitive disorder" instead of specifying "Alzheimer's Disease" in documents that may be seen by third parties, depending on the circumstances and preferences of the patient and family. Documentation should always be accurate and honest, but also sensitive to the social and emotional implications of the diagnosis.

5. Is there a difference in treatment between early-onset and late-onset Alzheimer's?

Although both forms are coded as 8A20 and share the same underlying pathology, there are some practical differences in management. Early-onset Alzheimer's (before age 65) often presents with faster progression and may have atypical presentations with greater impairment of language or visuospatial abilities. Younger patients generally have fewer medical comorbidities but face unique psychosocial challenges, including impact on employment, family responsibilities, and greater stigma. Genetic screening may be more relevant in early-onset cases, particularly with strong family history. Pharmacological interventions are essentially the same, but psychosocial support approaches should be adapted to the specific needs of younger patients and their families.

6. How to differentiate Alzheimer's Disease from normal age-related forgetfulness?

Benign senescent forgetfulness is characterized by occasional memory lapses that do not significantly interfere with daily activities, often related to names or specific details, with the ability to recall later or with cues. In Alzheimer's Disease, forgetfulness is progressively more frequent and severe, affecting important recent information, appointments, and conversations, with inability to recall even with cues. The crucial distinction is functional impairment: in normal aging, the person maintains complete independence in daily activities; in Alzheimer's, there is progressive decline in the ability to perform complex activities and, eventually, basic activities. Formal neuropsychological evaluation can objectively distinguish pathological decline from normal age-related variation. When in doubt, longitudinal follow-up often clarifies the diagnosis, as Alzheimer's demonstrates clear progression over time.

7. Do family members of Alzheimer's Disease patients have a higher risk of developing the disease?

Family history of Alzheimer's Disease increases the risk of developing the condition, but does not determine that family members will necessarily develop the disease. In the more common late-onset form, genetic factors contribute to risk but are not deterministic; multiple susceptibility genes, with APOE-ε4 being the most significant, modulate risk in combination with environmental and lifestyle factors. Autosomal dominant familial forms of early-onset, caused by mutations in specific genes (APP, PSEN1, PSEN2), are rare but confer very high risk. For concerned family members, genetic counseling may be appropriate, particularly in early-onset cases with strong family history. Modifiable lifestyle factors, including control of cardiovascular risk factors, regular physical activity, cognitive stimulation, and social engagement, may potentially reduce risk even in genetically susceptible individuals.

8. What is the life expectancy after diagnosis of Alzheimer's Disease?

Life expectancy after diagnosis of Alzheimer's Disease varies considerably, typically between 3 to 10 years, depending on multiple factors including age at diagnosis, severity at initial presentation, presence of medical comorbidities, and quality of care received. Patients diagnosed at younger ages generally survive longer, while diagnosis at very advanced age is associated with shorter survival. Disease progression is variable among individuals, with some patients experiencing rapid decline and others maintaining relative stability for prolonged periods. Medical complications, particularly infections (especially pneumonia), are common causes of mortality in advanced stages. High-quality supportive care, including adequate nutrition, prevention of complications, and appropriate treatment of intercurrent conditions, can positively influence survival and quality of life.

---

Conclusion:

Appropriate coding of Alzheimer's Disease using ICD-11 code 8A20 requires deep understanding of diagnostic criteria, ability to differentiate from other neurodegenerative conditions, and meticulous clinical documentation. This guide provides practical foundation for healthcare professionals to apply the code appropriately, contributing to accurate clinical records, effective public health planning, and ultimately better care for patients and families affected by this devastating condition.

External References

This article was prepared based on reliable scientific sources:

1. 🌍 WHO ICD-11 - Alzheimer's Disease
2. 🔬 PubMed Research on Alzheimer's Disease
3. 🌍 WHO Health Topics
4. 📊 Clinical Evidence: Alzheimer's Disease
5. 📋 Ministry of Health - Brazil
6. 📊 Cochrane Systematic Reviews

References verified on 2026-02-03